These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 35838218)

  • 1. Therapeutic Approaches for Intravascular Microthrombi-induced Acute Respiratory Distress Syndrome (ARDS) in COVID-19 Infection.
    Gopika KM; Sivajith S; Sugunan A; Sudheesh MS
    Curr Pharm Biotechnol; 2023; 24(8):970-987. PubMed ID: 35838218
    [TBL] [Abstract][Full Text] [Related]  

  • 2. COVID-19 Sepsis: Pathogenesis and Endothelial Molecular Mechanisms Based on "Two-Path Unifying Theory" of Hemostasis and Endotheliopathy-Associated Vascular Microthrombotic Disease, and Proposed Therapeutic Approach with Antimicrothrombotic Therapy.
    Chang JC
    Vasc Health Risk Manag; 2021; 17():273-298. PubMed ID: 34103921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Viral Coagulopathy in Patients With COVID-19: Treatment and Care.
    Kipshidze N; Dangas G; White CJ; Kipshidze N; Siddiqui F; Lattimer CR; Carter CA; Fareed J
    Clin Appl Thromb Hemost; 2020; 26():1076029620936776. PubMed ID: 32687449
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CLEC5A and TLR2 are critical in SARS-CoV-2-induced NET formation and lung inflammation.
    Sung PS; Yang SP; Peng YC; Sun CP; Tao MH; Hsieh SL
    J Biomed Sci; 2022 Jul; 29(1):52. PubMed ID: 35820906
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neutrophil elastase inhibitor (sivelestat) may be a promising therapeutic option for management of acute lung injury/acute respiratory distress syndrome or disseminated intravascular coagulation in COVID-19.
    Sahebnasagh A; Saghafi F; Safdari M; Khataminia M; Sadremomtaz A; Talaei Z; Rezai Ghaleno H; Bagheri M; Habtemariam S; Avan R
    J Clin Pharm Ther; 2020 Dec; 45(6):1515-1519. PubMed ID: 32860252
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute respiratory distress syndrome: potential of therapeutic interventions effective in treating progression from COVID-19 to treat progression from other illnesses-a systematic review.
    Ragel EJ; Harris LK; Campbell RA
    BMJ Open Respir Res; 2023 Sep; 10(1):. PubMed ID: 37657844
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel therapeutic targets for SARS-CoV-2-induced acute lung injury: Targeting a potential IL-1β/neutrophil extracellular traps feedback loop.
    Yaqinuddin A; Kashir J
    Med Hypotheses; 2020 Oct; 143():109906. PubMed ID: 32505910
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome: A structured summary of a study protocol for a randomised controlled trial.
    Smith K; Pace A; Ortiz S; Kazani S; Rottinghaus S
    Trials; 2020 Jul; 21(1):639. PubMed ID: 32660611
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Repurposing Multiple-Molecule Drugs for COVID-19-Associated Acute Respiratory Distress Syndrome and Non-Viral Acute Respiratory Distress Syndrome via a Systems Biology Approach and a DNN-DTI Model Based on Five Drug Design Specifications.
    Ting CT; Chen BS
    Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35409008
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Coagulopathy in COVID-19 and anticoagulation clinical trials.
    Zhang H; Lao Q; Zhang J; Zhu J
    Best Pract Res Clin Haematol; 2022 Sep; 35(3):101377. PubMed ID: 36494146
    [TBL] [Abstract][Full Text] [Related]  

  • 11. COVID-19-Associated Coagulopathy: An Exacerbated Immunothrombosis Response.
    Jayarangaiah A; Kariyanna PT; Chen X; Jayarangaiah A; Kumar A
    Clin Appl Thromb Hemost; 2020; 26():1076029620943293. PubMed ID: 32735131
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Severe COVID-19 with acute respiratory distress syndrome (ARDS) in a sickle cell disease adult patient: case report.
    Teulier M; Elabbadi A; Gerotziafas G; Lionnet F; Voiriot G; Fartoukh M
    BMC Pulm Med; 2021 Jan; 21(1):46. PubMed ID: 33514354
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical characteristics of pediatric patients with acute respiratory distress syndrome due to COVID-19.
    Marroquín-Yáñez ML; Medeiros M; Chávez-López A; Carrillo-López HA; Soto-Bautista NP; Jarillo-Quijada AE; Gómez-Murillo SY; Láscari-Jiménez EC; Ruiz-Quiñones G; Barrera-Alonzo CJ; Contras-Santiago EM; Hernández-Hernández M
    Bol Med Hosp Infant Mex; 2022; 79(3):170-179. PubMed ID: 35882022
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Likelihood of amyloid formation in COVID-19-induced ARDS.
    Sinha N; Thakur AK
    Trends Microbiol; 2021 Nov; 29(11):967-969. PubMed ID: 33795156
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of acute respiratory distress syndrome in patients with COVID-19 and influenza A (H7N9) virus infection.
    Ding L; Chen Y; Su N; Xu X; Yin J; Qiu J; Wang J; Zheng D
    Int J Infect Dis; 2022 Sep; 122():593-598. PubMed ID: 35793755
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and Safety of Thrombolysis in COVID-19 Related ARDS.
    Goyal A; Niwariya Y; Pawar N; Khurana A; Chaudhary P
    Recent Adv Antiinfect Drug Discov; 2023; 18(3):197-204. PubMed ID: 36237163
    [TBL] [Abstract][Full Text] [Related]  

  • 17. COVID-19-Associated acute respiratory distress syndrome (CARDS): Mechanistic insights on therapeutic intervention and emerging trends.
    Thapa K; Verma N; Singh TG; Kaur Grewal A; Kanojia N; Rani L
    Int Immunopharmacol; 2021 Dec; 101(Pt A):108328. PubMed ID: 34768236
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Direct Activation of Endothelial Cells by SARS-CoV-2 Nucleocapsid Protein Is Blocked by Simvastatin.
    Qian Y; Lei T; Patel PS; Lee CH; Monaghan-Nichols P; Xin HB; Qiu J; Fu M
    J Virol; 2021 Nov; 95(23):e0139621. PubMed ID: 34549987
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mesenchymal stem cells derived from perinatal tissues for treatment of critically ill COVID-19-induced ARDS patients: a case series.
    Hashemian SR; Aliannejad R; Zarrabi M; Soleimani M; Vosough M; Hosseini SE; Hossieni H; Keshel SH; Naderpour Z; Hajizadeh-Saffar E; Shajareh E; Jamaati H; Soufi-Zomorrod M; Khavandgar N; Alemi H; Karimi A; Pak N; Rouzbahani NH; Nouri M; Sorouri M; Kashani L; Madani H; Aghdami N; Vasei M; Baharvand H
    Stem Cell Res Ther; 2021 Jan; 12(1):91. PubMed ID: 33514427
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 2021 Acute Respiratory Distress Syndrome Update, With Coronavirus Disease 2019 Focus.
    Welker C; Huang J; Gil IJN; Ramakrishna H
    J Cardiothorac Vasc Anesth; 2022 Apr; 36(4):1188-1195. PubMed ID: 33781671
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.